PATENT CLAIM ANALYSIS

Application Number: 16024226
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["424", "134100"]

Abstract:
The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.

Claim (Index 58):
The heterologous chimeric protein of  claim 49 , wherein the heterologous chimeric protein is capable of causing activation of antigen presenting cells.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 94.0
- Lexical Diversity: 1.34091
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15853241', '16024228', '16024214', '16024218', '16024209']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8706779853775206
- 35 USC 102 Novelty (BERT): 0.6604361725485157
- Combined Prediction Score: 0.8496538040946201
- Mean Citation Score: 705.327062
- Max Citation Score: 733.3173
- Similarity Product: 614.7337657606603

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test